EGFR and Familial prostate cancer: Four pathways including for (1) hsa04010: MAPK signaling pathway, (2) hsa04151: PI3K-Akt signaling pathway, (3) hsa01521: EGFR tyrosine kinase inhibitor resistance, and (4) hsa05215: prostate cancer were in sum found to have accounted for ~79% (78 out of 99) of the total miRNAs.